

## PRESS RELEASE

### **ImaBiotech to conduct Pilot Study with GSK to assess ImaBiotech's Multimaging™ Technology**

Lille, France – May, 2015 –ImaBiotech will be conducting a pilot study with pharmaceutical company GlaxoSmithKline (GSK) on mass spectrometric derived imaging technology in the ADME and Toxicology fields.

ImaBiotech, a leading service provider for MALDI imaging focuses on quantification challenges and volumetric imaging data interpretation via the development of specially adapted multimodal imaging methods and dedicated software, known as Multimaging™. Multimaging™, a new Advanced Technology, significantly increases the capacity of Quantitative Mass Spectrometry Imaging, and classical histology techniques. It has the capability to quantitatively analyze the distribution of drug, metabolites and biomarkers at cellular level. This technology offers the potential to accelerate drug pharmacokinetic, pharmacology and toxicity studies.

Dr Jonathan Stauber, CEO of ImaBiotech commented, *“We are very pleased with the initiation of a pilot study with a major pharmaceutical company. GSK's interest in assessing ImaBiotech's Multimaging technology further underscores the expertise of ImaBiotech in the imaging field and the potential benefits that Multimaging technology offers.”*

Contact:

Jonathan Stauber, PhD,

Chief Executive Officer

E: [contact@imabiotech.com](mailto:contact@imabiotech.com)

T:+33 (0) 320 164 091

**ImaBiotech:**

Located in Europe (France), and North America (Cambridge, MA), ImaBiotech offers service with new imaging technologies, applications and software (Quantinetix™, Multimaging™). In order to accelerate drug development with innovative & proprietary imaging technologies, ImaBiotech offers Mass Spectrometry Imaging services to provide a cost effective solution to preclinical and clinical studies. This molecular technique is used for qualitative & quantitative efficacy and toxicity evaluations of drug candidates from the whole body to cell levels.